Cannabix Technologies Develops Version 2.0 of THC Breath Analyzer
Ryan Allway
May 11th, 2020
News, Top News
Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safety
VANCOUVER, British Columbia, May 11, 2020 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace, is pleased to report that the Company has developed a new version of its THC Breath Analyzer (“THCBA”) and is preparing for additional testing with the device. Company engineers have updated several components in the THCBA and have changed the form factor for improved handling. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment. The THCBA incorporates microfluidic sensor technology for the detection of THC from breath. New pictures of the THCBA version 2.0 advanced prototype device are available on the Company’s website (www.cannabixtechnologies.com) and included in this news release.
The THCBA has attractive features such as single-hand ergonomic design and single-stage direct breath capability. Testing to date, has shown from the time of sample intake, the device can provide results in under 5 minutes. The THCBA uses a disposable spit trap and provides easy to understand screen prompts for the positive and negative detection of THC in breath. Studies¹ have shown that breath is a better indicator of impairment than saliva, blood, or urine because THC is present in breath for a relatively short period of time (1-3 hours); whereas, it is excreted at detectable levels in other body fluids for many hours, days, or even weeks after smoking. This short time period of detection in breath aligns with the peak impairment window. The Company has been developing the THCBA with Dr. Mina Hoorfar at University of British Columbia (“UBC”) and has an exclusive technology license agreement with UBC.
In the immediate term, Cannabix scientists will be testing the THCBA 2.0 device with cannabis smokers in order to (a) have more cannabis user data to enhance the device’s machine learning database and (b) for continuous improvement purposes. It should be noted that testing with cannabis smokers under general COVID-19 restrictions in place has become more time-consuming as device sterilization and organizing multi-subject testing has become more onerous. In the THCBA 2.0 version, several components have been built using 3D printed technology for rapid prototyping and design flexibility, and engineers have begun experimenting with different materials and coatings that would be more advantageous in manufacturing processes. Since early March, our discussions with potential pilot/test-user groups were paused due to the COVID-19 pandemic, however the Company is pleased to report it is having renewed discussions with pilot-use cases and is actively navigating how such studies will be done with enhanced safety in mind.
Rav Mlait, CEO, stated, “Our team have been diligently pressing forward with development of our marijuana breathalyzer devices through the various constraints that the COVID-19 pandemic has presented us and our suppliers. We have improved the design and form factor of the THCBA and look forward to collecting more user data.”
“We are pleased to be continuing our collaborative research efforts with Cannabix towards the development of this technology under these challenging circumstances,” stated Dr. Hoorfar.
The Company reports it is granting 1,790,000 incentive stock options exercisable at $0.50 cents per share for five years to officers, directors and two years for consultants.
(1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104.
Himes S. et al. 2013. Cannabinoids in Exhaled Breath following Controlled Administration of Smoked Cannabis. Clinical Chemistry; 1780–1789.
Beck O, Sandqvist S, Dubbelboer I, Franck J. 2011. Detection of delta9-tetrahydrocannabinol in exhaled breath collected from cannabis users. J Anal Toxicol; 35:541– 4.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/a698bca7-6864-47ef-9a9a-a78a0901cdd4
https://www.globenewswire.com/NewsRoom/AttachmentNg/8d402dc0-d9cc-4e4b-910c-c04cdf7e7966
Cannabix Technologies Inc.
Cannabix Technologies Inc. THC Breath Analyzer Ver 2.0
Cannabix Technologies Inc.
Cannabix Technologies Inc. THC Breath Analyzer Ver 2.0
News Provided by
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Rubicon Holdings, Inc., a Washington State corporation, is a cannabis company focused on the United States adult use and medical marijuana markets.
Isodiol produces 99% Pure, Natural, Pharmaceutical Grade CBD. Isodiol and its team of collaborators are a group of companies that together grow, harvest, and process hemp on an industrial scale for the extraction of cannabidiol (CBD) to the highest available purity for worldwide distribution. From the largest source of farmed hemp, to wide-scale extraction and […]
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
